Following Seattle Genetics' (SGEN) and Astellas Pharma's announcement of positive results, from pivotal trial of the conjugated monoclonal antibody …

While waiting for Mueller’s report we stopped speculating on the stocks in what we saw as …

Biogen’s (BIIB) decision to discontinue the global Phase 3 trials, ENGAGE and EMERGE which is designed …

The Week in Review #39 During the Departed Week Three Prohost Portfolio Picks Hit Their 52-Week …

Atossa Genetics (ATOS) announced that the FDA has issued a “Safe to Proceed” letter under their “expanded …

Thanks to abundant cabozantinib sales’ revenues Exelixis (EXEL) is advancing a new generation of its medicines …

CRISPR Therapeutics' (CRSP) stock added around $8 today while reporting financial results for the fourth quarter …

Cytokinetics’ (CYTK) investigational product omecamtiv mecarbil, the firm’s potential treatment for heart failure with reduced ejection fraction, …

From the American Society of Clinical Oncology Genitourinary Cancers Symposium (ASCO GU) Prostate Cancer A presentation …

RegenxBio (RGNX), a clinical-stage gene therapy firm with a proprietary NAV® Technology Platform, will host an analyst and investor …